109680 ⎘
dsDNA viruses; Details; Adenoviridae; Mastadenovirus, e.g. human or simian adenoviruses Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
METHODS OF TREATING BLADDER CANCER
#2TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS
#3TUMOR-SELECTIVE E1A AND E1B MUTANTS
#4NASAL ANTI-CANCER THERAPIES
#5IMMUNOMODULATORY FUSION PROTEINS
#6ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR
#7ONCOLYTIC ADENOVIRUSES FOR TREATING CANCER
#8ONCOLYTIC ADENOVIRUSES ARMED WITH HETEROLOGOUS GENES
#9MEMBRANE LIPID COATED NANOPARTICLES AND METHOD OF USE
#10COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSES
#11A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter
#12ADENOVIRUS FOR ANTI-TUMOUR THERAPY
#13MODIFIED ADENOVIRUS
#14Adenovirus armed with bispecific T cell activator
#15Tumor-selective E1a and E1b mutants
#16GENERATION OF DIVERSE VIRAL LIBRARIES
#17ONCOLYTIC ADENOVIRUS WITH REPLICATION SELECTIVITY BASED ON STATUS OF P53 TRANSCRIPTIONAL ACTIVITY
#18MESENCHYMAL STEM CELLS THAT ENABLE TUMOR TARGETING IMPROVEMENT AND VIRUS MASS-PRODUCTION
#19DELIVERY OF SIALIDASE TO CANCER CELLS, IMMUNE CELLS AND THE TUMOR MICROENVIRONMENT
#20GENE DELIVERY SYSTEM CONTAINING RELAXIN GENE AND PHARMACEUTICAL COMPOSITION USING RELAXIN
#21DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODS
#22ADENOVIRUS COMPRISING A MODIFIED ADENOVIRUS HEXON PROTEIN
#23VIRUSES WITH MODIFIED CAPSID PROTEINS
#24MEMBRANE LIPID COATED NANOPARTICLES AND METHOD OF USE
#25METHOD FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS
#26Methods of treating bladder cancer
#27TREATMENT METHODS USING ADENOVIRUS
#28METHODS OF TREATING BLADDER CANCER
#29ONCOLYTIC NON-HUMAN ADENOVIRUSES AND USES THEREOF
#30Membrane lipid coated nanoparticles and method of use
#31Oncolytic adenovirus and checkpoint inhibitor combination therapy
#32METHODS AND COMPOSITIONS COMPRISING ENHANCED TARGETED IMMUNE GENE THERAPY FOR THE TREATMENT OF CANCER
#33COMBINATION OF A TLR7 MODULATING COMPOUND AND AN HIV VACCINE
#34ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING PEPTIDYLARGININE DEIMINASE AND TISSUE INHIBITOR OF METALLOPROTEINASE
#35PV-DELETED BOVINE ADENOVIRUS
#36ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING A MEMBER OF THE B7 FAMILY OF COSTIMULATORY LIGANDS AND ADA
#37METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY COMBINATION THERAPY
#38ADENOSOMES
#39DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
#40ONCOLYTIC ADENOVIRUS ENCODING A B7 PROTEIN
#41Cancer therapy
#42RECOMBINANT AAV VECTORS USEFUL FOR REDUCING IMMUNITY AGAINST TRANSGENE PRODUCTS
#43Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
#44TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS
#45Membrane lipid coated nanoparticles and method of use
#46Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells
#47Oncolytic adenoviruses armed with heterologous genes
#48Tumor-selective E1A and E1B mutants
#49Immunomodulatory fusion proteins
#50NOVEL APPLICATION OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR FOR MEDICAL PURPOSES
#51Methods of treating bladder cancer with an oncolytic virus
#52Recombinant adenoviruses and stem cells comprising same
#53Rodents having a humanized TMPRSS gene
#54ONCOLYTIC ADENOVIRUS COMPOSITIONS WITH ENHANCED REPLICATION PROPERTIES
#55MODIFIED ONCOLYTIC ADENOVIRUSES
#56TROPISM MODIFIED CANCER TERMINATOR VIRUS (AD.5/3 CTV;AD.5/3-CTV-M7)
#57Biomarkers and combination therapies using oncolytic virus and immunomodulation
#58Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
#59Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
#60Adenovirus armed with bispecific T cell activator
#61Adenovirus comprising an albumin-binding moiety
#62LIVE AND IN-VIVO TUMOR SPECIFIC CANCER VACCINE SYSTEM DEVELOPED BY CO-ADMINISTRATION OF EITHER AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE CHECKPOINT MODULATOR
#63Therapeutic compositions and methods of use for treating cancer
#64Oncolytic virus and method
#65Use of adenovirus and nucleic acids coding therefor
#66Membrane lipid coated viral nanoparticles and method of use
#67Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter
#68Detargeted adenovirus variants and related methods
#69TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS
#70MULTIPLE TRANSGENE RECOMBINANT ADENOVIRUS
#71Oncolytic adenoviruses for treating cancer
#72GENE DELIVERY SYSTEM CONTAINING RELAXIN GENE AND PHARMACEUTICAL COMPOSITION USING RELAXIN
#73PV-DELETED BOVINE ADENOVIRUS
#74Virus-PCION complex having enhanced antitumor effect by using electromagnetic field
#75Tropism modified cancer terminator virus (Ad.5/3 CTV;Ad.5/3-CTV-M7)
#76Tropic cell based virotherapy for the treatment of cancer
#77BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
#78Tumor-specific adenovirus vectors and therapeutic uses
#79Adenovirus armed with bispecific T cell engager
#80Adenovirus and immunomodulator combination therapy
#81Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
#82ONCOLYTIC ADENOVIRUSES FOR CANCER TREATMENT
#83Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of Cancer
#84Tumor-selective E1a and E1b mutants
#85Recombinant AAVS having useful transcytosis properties
#86Oncolytic adenovirus encoding a B7 protein or active fragment
#87Use of adenovirus and nucleic acids coding therefor
#88Treatment methods using adenovirus
#89COMBINING ADENOVIRUS AND CHEMOTHERAPEUTIC AGENTS FOR TREATING CANCER
#90Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein
#91Viral vector targeting cancer stem cells
#92Rodents having a humanized gene
#93Oncolytic adenoviruses armed with heterologous genes
#94METHODS FOR PREVENTING PLASTIC-INDUCED DEGRADATION OF BIOLOGICALS
#95Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
#96Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same
#97Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
#98Anti-tumor medicament based on adenovirus
#99Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
#100Oncolytic adenovirus encoding a B7 protein
#101Immunomodulatory fusion proteins
#102Detargeted adenovirus variants and related methods
#103Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
#104Oncolytic adenoviruses coding for bi-specific antibodies
#105RECOMBINANT AAV VECTORS USEFUL FOR REDUCING IMMUNITY AGAINST TRANSGENE PRODUCTS
#106Oncolytic adenovirus encoding a B7 protein
#107METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS
#108Use of adenovirus and nucleic acids coding therefor
#109Multitargeting onocolytic adenovirus, methods of use, and methods of making
#110Rodents having a humanized TMPRSS gene
#111Oncolytic adenovirus encoding a therapeutic protein or active fragment
#112Virus-PCION complex having enhanced antitumor effect by using electromagnetic field
#113Methods for reversing multiple resistance in animal cells
#114ONCOLYTIC TUMOR VIRUSES AND METHODS OF USE
#115Recombinant AAVS having useful transcytosis properties
#116Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof
#117Recombinant AAV vectors useful for reducing immunity against transgene products
#118Targeted adenoviruses and methods of making, isolating, and using
#119PROCESS FOR THE PREPARATION OF GROUP B ADENOVIRUSES
#120Oncolytic adenovirus encoding a B7 protein or active fragment
#121Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
#122Adenovirus comprising an albumin-binding moiety
#123ADENOVIRAL TARGETING, COMPOSITIONS AND METHODS THEREFOR
#124Group B adenovirus modified in the E4orf4 region
#125Oncolytic adenoviruses for cancer treatment
#126Oncolytic adenoviruses armed with heterologous genes
#127Method of making adenovirus and corresponding plasmids
#128Tropic cell based virotherapy for the treatment of cancer
#129In vivo individualized systemic immunotherapeutic method and device
#130Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same
#131ADENOVIRAL VECTORS AND METHODS AND USES RELATED THERETO
#132TREATMENT METHODS USING ADENOVIRUS
#133TREATMENT OF BRAIN CANCER WITH ONCOLYTIC ADENOVIRUS
#134Dosing regime and formulations for type B adenovirus
#135Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics
#136Use of adenoviruses and nucleic acids that code for said viruses
#137Simian Subfamily B Adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and Uses Thereof
#138Tropism modified cancer terminator virus (Ad.5/3 CTV;AD.5/3-CTV-M7)
#139Methods of propagating monkey adenoviral vectors
#140Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein
#141Matrix metalloproteinase cleavable protein polymers for cancer gene therapy
#142Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
#143Chimeric adenoviruses for use in cancer treatment
#144Biomarkers and combination therapies using oncolytic virus and immunomodulation
#145REIC-expressing adenovirus vector
#146Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same
#147Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence
#148Growth-regulated viral vector containing the aurora kinase promoter
#149Hexon Tat-PTD modified adenovirus and uses thereof
#150Anti-cancer adenoviruses
#151Chimeric adenoviruses for use in cancer treatment
#152Chimeric adenoviruses for use in cancer treatment
#153Chimeric adenoviruses for use in cancer treatment
#154HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME
#155Adenovirus E1A fragments for use in anti-cancer therapies
#156Compositions and methods for treatment of cancer using tissue-specific oncolytic adenoviruses
#157METHOD AND COMPOSITION FOR CREATING CONDITIONAL LETHALITY FOR VIRUS MUTANTS AND FOR ELIMINATING THE VIABILITY OF AN EUKARYOTIC CELL
#158Method and Composition to Increase Radiation-Induced Tumor Therapeutic Effects
#159Chimeric adenoviruses for use in cancer treatment
#160Methods of propagating monkey adenoviral vectors
#161THERAPEUTIC REGIMEN FOR TREATING CANCER
#162MICROBUBBLE ASSISTED VIRAL DELIVERY
#163Oncolytic adenoviruses for treating cancer
#164HUMAN MATRIX METALLOPROTEINASE-8 GENE DELIVERY ENHANCES THE ONCOLYTIC ACTIVITY OF A REPLICATING ADENOVIRUS
#165NON-AD5 ADENOVIRAL VECTORS AND METHODS AND USES RELATED THERETO
#166Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses
#167Tumor selective E1a and E1b mutants
#168METHODS FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS
#169NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES
#170REPLICATION COMPETENT VIRUSES CAPABLE OF SILENCING VIRUS INHIBITORY FACTOR EXPRESSION
#171Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small-molecule regulator
#172Promoter and viral vector containing the same
#173Adenoviruses Mutated In The VA Genes For Cancer Treatment
#174Oncolytic virus replicating selectively in tumor cells
#175Use of adenovirus and nucleic acids coding therefor
#176NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES
#177Methods for Reversing Multiple Resistance in Animal Cells
#178THERAPEUTIC REGIMEN FOR TREATING CANCER
#179Adenoviruses, nucleic acids that code for the same and the use of said viruses
#180Selectively replicating viral vectors
#181Simian subfamily B adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and uses thereof
#182CHIMERIC ADENOVIRUS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL USING THE SAME
#183Adenoviral vectors and methods and uses related thereto
#184TARGETED TUMOR THERAPY BY USE OF RECOMBINANT ADENOVIRUS VECTORS THAT SELECTIVELY REPLICATE IN HYPOXIC REGIONS OF TUMORS
#185Adenovirus with mutations in the endoplasmic reticulum retention domain of the E3-19K protein and their use in cancer treatment
#186ISOLATED DNA FRAGMENT OF THE HUMAN A33 PROMOTER AND ITS USE TO CONTROL THE EXPRESSION OF A HETEROLOGOUS GENE IN TUMOR CELLS
#187Oncolytic Adenoviruses and Uses Thereof
#188METHOD FOR THE PRODUCTION AND PURIFICATION OF RETROVIRAL VECTORS
#189Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof
#190Replication-competent anti-cancer vectors
#191RECOMBINANT ADENOVIRUS COMPRISING RECOMBINANT khp53 GENE AND THE PREPARATION METHOD AND USES THEREOF
#192Oncolytic Adenoviruses for Cancer Treatment
#193Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
#194Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
#195Adenovirus 36 E4 orf 1 gene and protein and their uses
#196Chimeric adenoviruses for use in cancer treatment
#197ADENOVIRUS STATUS AS A PREDICTOR OF BODY COMPOSITION CHANGE, DISEASE STATUS, AND TREATMENT OUTCOMES
#198Recombinant gene of adenovirus vector and p53 gene for treating proliferative diseases
#199ADENOVIRUSES MUTATED IN THE VA GENES FOR CANCER TREATMENT
#200Recombinant protein production in a human cell
#201Application of heparin-binding epidermal growth factor-like growth factor for medical purposes
#202Tumor-targeting gene-virus zd55-il 24,its construction method and application thereof
#203Pan cancer oncolytic vectors and methods of use thereof
#204RECOMBINANT ADENOVIRAL VECTORS AND METHODS OF USE
#205Adenoviral vectors having a protein IX deletion
#206Methods and reagents for the enhancement of virus transduction in the bladder epithelium
#207Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small-molecule regulator
#208Adenoviral vectors having a protein IX deletion
#209Oncolytic Adenovirus Armed with Therapeutic Genes
#210Recombinant protein production in a human cell
#211Method and reagents for the enhancement of virus transduction in the bladder epithelium
#212Cancer-targeted viral vectors
#213Adenoviral vectors having a protein IX deletion
#214Combined gene therapy for the treatment of macroscopic gliomas
#215ADENOVIRAL VECTORS HAVING A PROTEIN IX DELETION
#216Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
#217Methods and reagents for the enhancement of virus transduction in the bladder epithelium
#218Oncolytic adenoviral vectors encoding GM-CSF
#219Methods and reagents for the enhancement of virus transduction in the bladder epithelium
#220Methods and reagents for the enhancement of virus transduction in the bladder epithelium
#221Liquid adenovirus formulations
#222HUMAN MATRIX METALLOPROTEINASE-8 GENE DELIVERY ENHANCES THE ONCOLYTIC ACTIVITY OF A REPLICATING ADENOVIRUS
#223METHODS AND COMPOSITIONS FOR GENE THERAPY
#224Formulation for adenovirus storage
#225Adenoviruses mutated in the VA genes for cancer treatment
#226Methods and Compositions for Viral Enhancement of Cell Killing
#227Methods of producing erythropoietin isoforms comprising Lewis-X structures and high sialic acid content and compositions of the same
#228Tmprss2 Regulatory Sequences and Uses Thereof
#229Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
#230RECOMBINANT ADENOVIRAL VECTORS AND METHODS OF USE
#231Methods and compositions to induce antitumor response
#232Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin
#233THERAPEUTIC REGIMEN FOR TREATING CANCER
#234Method for the production and purification of adenoviral vectors
#235Composition for the preservation of viruses
#236Cancer gene therapeutic drug
#237Cancer gene therapeutic drug
#238Adenoviral vectors having a protein IX deletion
#239Novel use of adenoviruses and nucleic acids that code for said viruses
#240Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
#241Recombinant protein production in a human cell
#242Method of preparing a proliferation-regulated recombinant adenoviral vector efficiently and kit for preparing the same
#243Recombinant adenoviral vector and method of use
#244Adenoviral vectors having a protein IX deletion
#245Nucleic acid delivery
#246Addition of transgenes into adenoviral vectors
#247Adenoviral vectors for treating diseases
#248PROPHYLACTIC AND THERAPEUTIC TREATMENT OF THE DUCTAL EPITHELIUM OF A MAMMARY GLAND FOR CANCER
#249Conditionally replicating viruses and methods for cancer virotherapy
#250Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
#251Adenoviral vectors for treating diseases
#252Adenoviral vectors for treating diseases
#253Use of adenoviruses mutated in the VA genes for cancer treatment
#254Human prolyl isomerase 1 (PIN 1) promoter and uses thereof
#255Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
#256Methods and compositions comprising DNA damaging agents and p53
#257Recombinant adenoviral vectors and methods of use
#258Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
#259Recombinant expression of factor VIII in human cells
#260Novel use of adenoviruses and nucleic acids coding therefor
#261Adenoviruses, nucleic acids coding therefor, and use thereof
#262Adenoviral vectors having a protein IX deletion
#263Adenoviral vectors having a protein IX deletion
#264Replication-competent anti-cancer vectors
#265Target cell-specific adenoviral vectors containing E3 and methods of use thereof
#266Cancer - targeted viral vectors
#267Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
#268Oncolytic adenoviral vectors encoding GM-CSF
#269Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
#270Vectors and methods for gene transfer
#271Chimeric adenoviruses for use in cancer treatment
#272Conditionally replicative adenovirus to target the Rb and Rb-related pathways
#273Compositions and methods for treating cancer with an oncolytic viral agent
#274Viruses with enhanced lytic potency
#275Pan cancer oncolytic vectors and methods of use thereof
#276Oncolytic adenoviral vectors encoding GM-CSF
#277Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
#278Formulation of adenovirus for gene therapy
#279Anti-neoplastic viral agents
#280Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
#281Methods and compositions for viral enhancement of cell killing
#282Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
#283Hepatocellular carcinoma specific promoter and uses thereof
#284Modified adenovirus containing a fiber replacement protein
#285Method for the production and purification of adenoviral vectors
#286Methods and compositions comprising DNA damaging agents and p53
#287Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof
#288Adenovirus E1B-55K single amino acid mutants and methods of use
#289Defective recombinant adenoviruses expressing cytokines for antitumor treatment
#290Subgroup B adenoviral vectors for treating disease
#291Composition for viral preservation
#292Tumor-specific promotor and use thereof
#293Nucleic acid delivery
#294TAA/ecdCD40L oncolytic virus